Related Experiment Video
Updated: Aug 3, 2026

Three Dimensional Vestibular Ocular Reflex Testing Using a Six Degrees of Freedom Motion Platform
Published on: May 23, 2013
[Clinical effect of ligustrazine in patients with benign paroxysmal positional vertigo]
1First Affiliated Hospital of Beijing Medical University.
Abstract:
The therapeutic effect of Ligustrazine was studied in patients with benign paroxysmal positional vertigo (BPPV). 11 cases were given Ligustrazine 100 mg daily (iv. or im.), another 11 cases were given Valium and Diphenidol as the control group. The results were as follows: In Ligustrazine group, the average curative time was 37 days. In the control group, the average curative time was 72 days. This result suggests that Ligustrazine is a useful drug in the treatment of BPPV. It is believed that the cause of BPPV is due to the occlusion of the anterior vestibular artery. Ligustrazine has the effect of improving microcirculation of the cochlea.
More Related Videos
05:02Using Unidirectional Rotations to Improve Vestibular System Asymmetry in Patients with Vestibular Dysfunction
Published on: August 30, 2019
08:57Measuring the Influence of Magnetic Vestibular Stimulation on Nystagmus, Self-Motion Perception, and Cognitive Performance in a 7T MRT
Published on: March 3, 2023
Related Concept Videos
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Equilibrium and Balance
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Anxiolytic Drugs: Benzodiazepines and Buspirone
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists